Profile data is unavailable for this security.
About the company
Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.
- Revenue in USD (TTM)0.00
- Net income in USD-194.34m
- Incorporated2015
- Employees108.00
- LocationPharvaris NVEmmy Noetherweg 2LEIDEN 2333 BKNetherlandsNLD
- Phone+31 712036410
- Websitehttps://pharvaris.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.63bn | 186.00 | -- | 2.73 | -- | 628.71 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -15.08m | 1.65bn | 31.00 | -- | 20.54 | -- | -- | -0.2004 | -0.2004 | 0.00 | 0.961 | 0.00 | -- | -- | 0.00 | -21.65 | -46.71 | -35.55 | -55.72 | -- | -- | -- | -- | -- | -38.28 | 0.00 | -- | -- | -- | -130.47 | -- | -- | -- |
| Nurix Therapeutics Inc | 83.98m | -264.46m | 1.66bn | 317.00 | -- | 3.04 | -- | 19.73 | -3.04 | -3.04 | 0.969 | 5.29 | 0.1237 | -- | -- | 264,921.10 | -38.96 | -36.56 | -45.01 | -43.34 | -- | -- | -314.90 | -316.85 | -- | -- | 0.00 | -- | 53.95 | 36.35 | -36.62 | -- | 25.19 | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.66bn | 65.00 | -- | 3.49 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.40 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.70bn | 580.00 | -- | -- | -- | 2.83 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Tango Therapeutics Inc | 66.50m | -100.52m | 1.70bn | 155.00 | -- | 8.79 | -- | 25.52 | -0.9208 | -0.9208 | 0.593 | 1.43 | 0.2364 | -- | -- | 429,038.70 | -35.74 | -- | -39.69 | -- | -- | -- | -151.15 | -283.69 | -- | -- | 0.00 | -- | 15.17 | -- | -28.07 | -- | -- | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.71bn | 263.00 | -- | 5.40 | -- | 12.70 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.71bn | 74.00 | -- | 10.20 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
| Pharvaris NV | 0.00 | -194.34m | 1.75bn | 108.00 | -- | 4.79 | -- | -- | -3.46 | -3.46 | 0.00 | 5.71 | 0.00 | -- | -- | 0.00 | -50.22 | -36.71 | -53.72 | -38.87 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -33.06 | -- | 109.04 | -- |
| MannKind Corp | 313.79m | 28.76m | 1.76bn | 407.00 | 61.98 | -- | 47.42 | 5.62 | 0.0926 | 0.0926 | 1.02 | -0.1451 | 0.6545 | 2.52 | 17.64 | 770,975.40 | 6.00 | -14.54 | 7.40 | -19.49 | 78.49 | 65.89 | 9.16 | -28.96 | 3.04 | 2.68 | 1.14 | -- | 43.50 | 35.27 | 331.09 | -- | 30.46 | -- |
| Ardelyx Inc | 398.23m | -56.55m | 1.76bn | 395.00 | -- | 11.43 | -- | 4.43 | -0.2364 | -0.2364 | 1.66 | 0.635 | 0.9326 | 2.57 | 6.14 | 1,008,187.00 | -13.24 | -35.80 | -16.15 | -45.22 | 88.21 | 86.06 | -14.20 | -80.49 | 4.11 | -2.07 | 0.5671 | -- | 168.06 | 129.14 | 40.76 | -- | 25.48 | -- |
| Semnur Pharmaceuticals Inc | 0.00 | -1.46m | 1.84bn | -- | -- | -- | -- | -- | -0.4678 | -0.4678 | 0.00 | -4.05 | 0.00 | -- | -- | -- | -5.54 | -- | -7.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -126.45 | -- | -- | -- |
| Stoke Therapeutics Inc | 205.63m | 40.57m | 1.84bn | 128.00 | 48.82 | 5.76 | 43.34 | 8.95 | 0.66 | 0.66 | 3.52 | 5.59 | 0.6293 | -- | 35.68 | 1,606,500.00 | 12.41 | -34.04 | 14.44 | -37.36 | -- | -- | 19.73 | -749.56 | -- | -- | 0.00 | -- | 316.34 | -- | 15.01 | -- | -34.11 | -- |
| Olema Pharmaceuticals Inc | 0.00 | -149.96m | 1.86bn | 122.00 | -- | 5.28 | -- | -- | -1.81 | -1.81 | 0.00 | 4.48 | 0.00 | -- | -- | 0.00 | -51.48 | -31.26 | -58.78 | -33.05 | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -- | -- | -33.95 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Pharvaris NV's reporting currency: US Dollar USD
31.91%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 6.40m | 9.99% |
| Viking Global Investors LPas of 30 Sep 2025 | 3.65m | 5.70% |
| Commodore Capital LPas of 30 Sep 2025 | 2.42m | 3.78% |
| Paradigm BioCapital Advisors LPas of 30 Sep 2025 | 1.84m | 2.87% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 1.67m | 2.61% |
| Cormorant Asset Management LPas of 30 Sep 2025 | 1.36m | 2.13% |
| Saturn V Capital Management LPas of 30 Sep 2025 | 886.33k | 1.38% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 816.81k | 1.28% |
| Octagon Capital Advisors LPas of 30 Sep 2025 | 722.60k | 1.13% |
| Kynam Capital Management LPas of 30 Sep 2025 | 675.00k | 1.05% |
More ▼
Data from 30 Sep 2025 - 30 Sep 2025Source: FactSet Research Systems Inc.
